Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Cause-specific mortality in women receiving hormone replacement therapy.

Schairer C, Adami HO, Hoover R, Persson I.

Epidemiology. 1997 Jan;8(1):59-65.

PMID:
9116097
2.

Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden.

Falkeborn M, Persson I, Terént A, Adami HO, Lithell H, Bergström R.

Arch Intern Med. 1993 May 24;153(10):1201-9.

PMID:
8388207
3.

Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for 'healthy drug-user' effect.

Yuen J, Persson I, Bergkvist L, Hoover R, Schairer C, Adami HO.

Cancer Causes Control. 1993 Jul;4(4):369-74.

PMID:
8394149
4.

Risk of endometrial cancer following estrogen replacement with and without progestins.

Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R, Lindgren A, Correia N, Persson I.

J Natl Cancer Inst. 1999 Jul 7;91(13):1131-7.

5.

Estrogen-progestin replacement therapy and endometrial cancer.

Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM.

J Natl Cancer Inst. 1997 Aug 6;89(15):1110-6.

6.

Breast cancer risk with postmenopausal hormonal treatment.

Collins JA, Blake JM, Crosignani PG.

Hum Reprod Update. 2005 Nov-Dec;11(6):545-60. Review. Erratum in: Hum Reprod Update. 2006 May-Jun;12(3):331.

7.

Comparative cardiovascular effects of different progestins in menopause.

Rosano GM, Fini M.

Int J Fertil Womens Med. 2001 Sep-Oct;46(5):248-56. Review.

PMID:
11720197
8.

Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women.

de Lignières B, de Vathaire F, Fournier S, Urbinelli R, Allaert F, Le MG, Kuttenn F.

Climacteric. 2002 Dec;5(4):332-40.

PMID:
12626212
9.

Hormone replacement therapy and cancer.

[No authors listed]

Gynecol Endocrinol. 2001 Dec;15(6):453-65. Review.

PMID:
11826770
10.
12.

The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women.

Alexandersen P, Tankó LB, Bagger YZ, Qin G, Christiansen C.

Climacteric. 2006 Apr;9(2):108-18.

PMID:
16698657
13.

Postmenopausal hormone therapy: cardiovascular risks.

[No authors listed]

Prescrire Int. 2003 Apr;12(64):65-9.

PMID:
12674130
14.

Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.

McGonigle KF, Karlan BY, Barbuto DA, Leuchter RS, Lagasse LD, Judd HL.

Gynecol Oncol. 1994 Oct;55(1):126-32.

PMID:
7959253
15.

Postmenopausal women and cardiovascular risk: impact of hormone replacement therapy.

Rosano GM, Fini M.

Cardiol Rev. 2002 Jan-Feb;10(1):51-60. Review.

PMID:
11790270
16.

Estrogen replacement therapy in patients with early breast cancer.

Natrajan PK, Gambrell RD Jr.

Am J Obstet Gynecol. 2002 Aug;187(2):289-94; discussion 294-5.

PMID:
12193914
17.

Postmenopausal estrogen and progestin use in relation to breast cancer risk.

Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ.

Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):593-600.

18.

Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer.

Jick SS, Hagberg KW, Kaye JA, Jick H.

Obstet Gynecol. 2009 Jan;113(1):74-80. doi: 10.1097/AOG.0b013e31818fdde4.

PMID:
19104362
19.

Endometrial cancer in postmenopausal women using estradiol-progestin therapy.

Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O.

Obstet Gynecol. 2009 Dec;114(6):1197-204. doi: 10.1097/AOG.0b013e3181bea950.

PMID:
19935019
20.

Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States).

Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN.

Cancer Causes Control. 1994 Nov;5(6):491-500.

PMID:
7827235
Items per page

Supplemental Content

Support Center